Format

Send to

Choose Destination
Oral Oncol. 2017 Sep;72:26-31. doi: 10.1016/j.oraloncology.2017.07.001. Epub 2017 Jul 8.

nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma.

Author information

1
Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, United States; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States. Electronic address: dadkins@wustl.edu.
2
Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, United States.
3
Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, United States; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States.
4
Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, United States.
5
Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States; Department of Otolaryngology, Washington University School of Medicine, St. Louis, MO, United States.
6
Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States; Division of Public Health Sciences; Washington University School of Medicine, St. Louis, MO, United States.

Abstract

OBJECTIVES:

To explore the effect of incorporating cetuximab into induction chemotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC).

MATERIALS AND METHODS:

Retrospective comparative analysis of two consecutive prospective phase II trials was performed: trial 1 with nab-paclitaxel/cisplatin/5-FU and cetuximab (APF-C; n=30) and trial 2 with APF (n=30). Patients were scheduled to receive chemoradiation therapy (CRT) with cisplatin. T2-4 classification oropharynx (OP)/larynx/hypopharynx SCC were included. Cumulative incidence of death of disease (CIDD), overall survival (OS), and cumulative incidence of relapse were compared between APF-C and APF.

RESULTS:

No significant differences in patient or tumor characteristics were noted between the groups. Median follow-up of surviving patients was 52 (25-95) months. Relapse occurred in 5 (17%) patients treated with APF-C and in 2 (7%) treated with APF (p=0.37). In human papillomavirus (HPV)-related OPSCC (n=34), the CIDD at 52months was 3.4% with APF-C and 2.6% with APF and the two-year OSs were 94%. In HPV-unrelated HNSCC (n=25), the CIDD at 52months was 4.4% with APF-C and 3.3% with APF and two-year OSs were 83% and 92%, respectively. CIDD or OS did not differ when stratified by treatment group and HPV status (CIDD: p=0.80; OS: p=0.30).

CONCLUSION:

This exploratory retrospective comparative analysis demonstrated no significant difference in CIDD, OS, or cumulative incidence of relapse between patients treated with APF-C or APF.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00736944 NCT01566435.

KEYWORDS:

Cetuximab; Head and neck cancer; Induction chemotherapy

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center